Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.
You may also be interested in...
Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?
Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.
European Generics Need To Climb Into Niches, Huddle Together For Growth
The current situation for Europe’s generic medicines manufacturers is at best uncomfortable due to significant pricing pressures and increasing competition, but the reality is that it is likely to get far worse.
German Pharmaceutical Law Removes Incentives For Orphan Drug R&D
National biotechnology and pharmaceutical industry associations object to certain provisions in the proposed German law on restructuring the pharma sector, AMNOG, that would add health technology assessments for orphan drugs.